Trailstone and Glennmont Partners Sign Route to Market PPA for 84 MW Wind Portfolio in Italy
Trailstone Group (“Trailstone”), a global energy and technology company, announced today that it has signed a route to market Power Purchase Agreement (PPA) with Glennmont Partners from Nuveen (“Glennmont”), one of the world’s largest renewable energy investment managers, for 84 MW of wind capacity in Italy. This deal is the latest in a longstanding relationship between Trailstone and Glennmont that began in 2016. It brings the total wind capacity being managed by Trailstone in Italy in 2023 to over 500 MW and the total number of renewable assets being managed by Trailstone across Europe to over 4.3 GWs.
Through this transaction, Trailstone will utilize its market access, expertise, and proprietary renewables optimization platform to reduce balancing risk and maximize trading revenues for Glennmont’s wind generation assets in Italy. Route to market PPAs offered by Trailstone allow owners of power generation, such as Glennmont, to access the forward power markets, generate revenues from the balancing mechanism and ancillary services markets, access dispatch service and meet minimum revenue guarantees.
Ante Pogacic, Global Head of Power and Renewables at Trailstone said: “Trailstone is proud to continue our partnership with Glennmont to provide tech-enabled risk management and asset optimization solutions for their wind assets in Italy. Deals such as this are necessary to accelerate the clean energy transition by reducing the growing market risks faced by owners of wind and solar assets.”
Francesco Cacciabue, Partner at Glennmont said: “We’re pleased to continue our longstanding relationship with Trailstone and work with their expert team to optimize our wind portfolio in Italy. This route to market PPA will ensure that our carefully selected, risk-managed investments deliver sustained performance and reliable returns.”
Trailstone’s proprietary optimization platform uses robust weather models, data analytics and Artificial Intelligence (AI) to better predict renewable energy supply and optimize returns for asset owners. Trailstone’s experienced risk management and trading teams use the platform to manage imbalances caused by weather related production risks, lowering the barriers to entry for asset developers and enabling the deployment of more wind and solar generation. At the grid level, improving the effectiveness and efficiency with which renewables are managed enables more assets to connect to the grid, lowering reserve requirements and costs, all of which provide a better environment for the end consumer.
About Trailstone
Trailstone is a global renewable energy trading and asset management firm that provides risk management and energy optimization to improve production and financial returns. The company offers a fully automated end-to-end renewable power management platform, backed by a successful track record in energy trading. Trailstone’s proprietary technology leverages data analytics and meteorology to offer robust modeling, forecasting and trading capabilities to its clients. Trailstone was founded in April 2013. To date, Trailstone has helped optimize more than 18,000 MWs of renewable energy assets and operates in 16 countries. Learn more at www.trailstonegroup.com.
About Glennmont Partners from Nuveen
Glennmont Partners from Nuveen is a leading infrastructure equity firm that has been at the forefront of clean energy investments for over a decade. It is owned by Nuveen, which manages $1.3 trillion in assets on behalf of institutions and individuals around the world. Glennmont is one of Europe’s largest specialist renewable energy fund managers with approximately €2 billion invested in over 30 clean power projects such as wind farms, solar photovoltaic and biomass that together produce more than 1,500MW of energy across the European Union. (www.glennmont.com)
Glennmont Partners is a trading name of Clean Energy Partners LLP and Glennmont Asset Management Limited, both of which are authorized and regulated by the Financial Conduct Authority.
For further information, visit www.glennmont.com
Follow Glennmont on twitter: @glennmont
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230508005019/en/
Contact information
Media Inquiries:
T
railstone, Rebecca Collins
trailstone@antennagroup.com
Glennmont, Orlando Wind-Cowie
o.wc@lodestonecommunications.com
+44 (0) 7707 985 967
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release
Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release
Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r
Vertex Presents New Data on CASGEVY ® , Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 14:01:00 EET | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and TDT ages 12 years and older, will be presented at the American Society of Hematology (ASH) Annual Meeting. CASGEVY is currently approved for eligible people ages 12 years and older with SCD or TDT in the United States, Great Britain, the European Union, the Kingdom of Saudi Arabia, the Kingdom of Bahrain, Kuwait, Qatar, Canada, Switzerland and the United Arab Emirates. “These results — the first clinical data ever presented on any genetic therapy for children ages 5-11 years with SCD — again demonstrate the tr
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 13:31:00 EET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 01:49:00 EET | Press release
Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive Officer, Lattice Semiconductor. The annual GSA Awards celebrate the accomplishments of the semiconductor indu
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom